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Abstract
Inhibition of chymase is likely to divulge therapeutic ways for the treatment of cardiovascular diseases, and fibrotic
disorders. To find novel and potent chymase inhibitors and to provide a new idea for drug design, we used both ligand-
based and structure-based methods to perform the virtual screening(VS) of commercially available databases. Different
pharmacophore models generated from various crystal structures of enzyme may depict diverse inhibitor binding modes.
Therefore, multiple pharmacophore-based approach is applied in this study. X-ray crystallographic data of chymase in
complex with different inhibitors were used to generate four structure–based pharmacophore models. One ligand–based
pharmacophore model was also developed from experimentally known inhibitors. After successful validation, all
pharmacophore models were employed in database screening to retrieve hits with novel chemical scaffolds. Drug-like hit
compounds were subjected to molecular docking using GOLD and AutoDock. Finally four structurally diverse compounds
with high GOLD score and binding affinity for several crystal structures of chymase were selected as final hits. Identification
of final hits by three different pharmacophore models necessitates the use of multiple pharmacophore-based approach in
VS process. Quantum mechanical calculation is also conducted for analysis of electrostatic characteristics of compounds
which illustrates their significant role in driving the inhibitor to adopt a suitable bioactive conformation oriented in the
active site of enzyme. In general, this study is used as example to illustrate how multiple pharmacophore approach can be
useful in identifying structurally diverse hits which may bind to all possible bioactive conformations available in the active
site of enzyme. The strategy used in the current study could be appropriate to design drugs for other enzymes as well.
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Introduction
Cardiovascular diseases are the leading cause of death in the
developed world and are now on course to be emerging as the
major cause of death in the developing world [1]. One particular
manifestation of cardiovascular diseases, heart failure (HF), is
dramatically increasing in frequency. A link between heart failure
and chymase has been ascribed, and there is an interest to develop
a specific chymase inhibitor as a new therapeutic regimen for the
disease [2]. Chymase (EC 3.4.21.39) which is a chymotrypsin-like
enzyme expressed in the secretory granule of mast cells, catalyzes
the production of angiotensin I (Ang I) to angiotensin II (Ang II) in
vascular tissues [3]. The octapeptide hormone, Ang II targets
human heart and plays an important role in vascular proliferation,
hypertension and atherosclerosis [4]. Conversion of Ang I to Ang
II is also catalyzed by well-known angiotensin-converting enzyme
(ACE), which is a metallo-proteinase with dipeptidyl-carboxypep-
tidase activity. However, chymase catalyzes the production of Ang
II in vascular tissues even when ACE is blocked (Figure 1).
Chymase converts Ang I to Ang II with greater efficiency and
selectivity than ACE [5]. The rate of this conversion by chymase is
approximately four fold higher than ACE. In order to generate
Ang II, human chymase cleaves the Ang I at Phe8-His9 peptide
bond. Chymase shows enzymatic activity immediately after its
release into the interstitial tissues at pH 7.4 following various
stimuli in tissues. Chymase also converts precursors of transform-
ing growth factor-b (TGF-b) and matrix metalloproteinase
(MMP)-9 to their active forms thus contributing to vascular
response to injury (Figure 1). Both TGF-b and MMP-9 are
involved in tissue inflammation and fibrosis, resulting in organ
damage [6]. Previous studies have demonstrated the involvement
of chymase in the escalation of dermatitis and chronic inflamma-
tion pursuing cardiac and pulmonary fibrosis [7]. Therefore,
inhibition of chymase is likely to divulge therapeutic ways for the
treatment of cardiovascular diseases, allergic inflammation, and
fibrotic disorders. Chymase inhibition may also be useful for
preventing the progression of type 2 diabetes, along with the
prevention of diabetic retinopathy [8]. Moreover, role of chymase
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in inflammation has prompted its restorative value in diseases such
as chronic obstructive pulmonary disease (COPD) and asthma [9].
Drug discovery and development is a time-consuming and
costly procedure. Therefore, application and development of
computational methods for lead generation and lead optimization
in the drug discovery process are of immense importance in
reducing the cycle time and cost as well as to amplify the
productivity of drug discovery research [10]. These computational
methods are generally categorized as ligand-based methods and
(receptor) structure-based methods. In case of ligand-based
methods, when biological activities of multiple hits are known, a
more sophisticated class of computational techniques known as
pharmacophore identification methods is often employed to
deduce the essential features required for the biological activity
[11]. A pharmacophore is an abstract description of molecular
features which are necessary for molecular recognition of a ligand
by a biological macromolecule. Due to the advantage in efficiency
in the virtual screening, the pharmacophore model method is now
a potent tool in the area of drug discovery [12]. However, the
often cited drawback of the ligand-based methods is that they do
not provide detailed structural information to help medicinal
chemists in designing new molecules. The availability of the
detailed structural information is critical especially during the lead
optimization stage of the discovery process. While, structure-based
pharmacophore methodology which involves generation of
pharmacophore models directly from complex crystal structures
is more reliable because it imposes the necessary constraints
required for interaction and selectivity. Diverse inhibitor binding
modes can be attained from ligand-based and structure-based
pharmacophore modeling methodologies especially if many
complex crystal structures are available for the target enzyme.
In this view, a strategy that integrates the advantages of multiple
pharmacophore modeling and molecular docking approaches has
been applied for the current study in order to identify compounds
that contain the important chemical features to inhibit chymase
enzyme. This strategy has been successfully applied for identifi-
cation of compounds from the chemical database that can strongly
bind at the active site of the target and thereby act as competitive
inhibitors to the chymase. Finally, four druglike compounds from
the database are reported as possible inhibitors for chymase
enzyme. In final phase of current study, we have carried out herein
Density Functional Theory-based quantum mechanical studies on
potent hits retrieved by newly developed pharmacophore models.
Various electronic properties such as LUMO, HOMO, and
locations of molecular electrostatic potentials, are calculated for
electronic features analysis. In general, the outcome of this
research exertion demonstrates how multiple pharmacophore
modeling accompanied with molecular docking, can be a
significant approach in identification of hits compounds with high
structurally diversity which may bind to all possible bioactive
conformations available in the active site of enzyme. Moreover,
this study is also expected to explore the molecular mechanism by
which these compounds act and can be further utilized to get
compounds with better activity by rational modification.
Materials and Methods
Receptor-ligand pharmacophore generation (structure-
based approach)
Structure-based pharmacophore model utilizes the interactions
between receptor-ligand complexes to generate a hypothesis [13].
As deposit of X-ray crystal structures in PDB is growing rapidly,
the structure-based methods have become increasingly important.
The information about the protein structure is a good source to
bring forth the structure-based pharmacophore and used as first-
screening before docking studies. To date, six crystal structures
have been determined for human chymase as listed in Table 1.
The four crystal structures which are co-crystallized with four
different inhibitors include 3N7O, 1T31, 3SON, and 2HVX and
their inhibitors are depicted in Figure 2. These crystal structures
were downloaded from the Protein Data Bank (PDB). PDB is a
repository for the 3-D structural data of large biological molecules,
such as proteins and nucleic acids. The data, typically obtained by
X-ray crystallography or NMR spectroscopy and submitted by
biologists and biochemists from around the world, are freely
accessible on the Internet via the website (http://www.rcsb.org).
The PDB is overseen by an organization called the Worldwide
Protein Data Bank, wwPDB. After downloading the desired crystal
structures of chymase complexes, these four receptor-ligand
complexes were used for development of structure-based pharma-
cophore models. The Receptor-Ligand Pharmacophore Generation
protocol of Accelrys Discovery Studio v3.0 (DS), Accelrys, San
Diego, USA, was applied to accomplish this task with default
parameters. This protocol generates selective pharmacophore
models based on receptor-ligand interactions. First, a set of
features from the binding ligand is identified. The following
predefined feature types are considered: hydrogen bond acceptor
(HBA), hydrogen bond donor(HBD), hydrophobic(HY), negative
ionizable(NI), positive ionizable(PI), ring aromatic(RA). Second,
the pharmacophore models are ranked based on a measure of
sensitivity and specificity and the top models are returned. The
pharmacophore models are enumerated and then the selectivity is
estimated based on a Genetic Function Approximation GFA)
model. The GFA model for the selectivity of a pharmacophore is
built from a training set of 3285 pharmacophore models. This set
is used for searching the CapDiverse database in DS. The
logarithmic values of the number of database search hits are used
as the targets (a value of 21.0 is used if no hit is retrieved from the
search). The number of total features in pharmacophore models
and the feature-feature distance bin values are used as the
descriptors for training the GFA model.
Common feature pharmacophore generation (ligand-
based approach)
Chemical compounds with their experimentally known chymase
inhibitory activity(IC50) data were obtained from the literature
such as life science journals, and a small database was compiled
[14,15,16,17,18]. Chemical structures of these compounds were
downloaded from BindingDB database(http://www.bindingdb.
org). BindingDB is a public, web-accessible database of measured
binding affinities, focusing chiefly on the interactions of protein
considered to be drug-targets with small, drug-like molecules.
BindingDB contains 947,406 binding data, for 6,667 protein
targets and 393,164 small molecules. Five diverse compounds with
the IC50 values less than or equal to 18 nM were selected as
Figure 1. Chymase-dependent conversion of angiotensin I to
angiotensin II and precursors of TGF-b and MMP-9 to their
active forms.
doi:10.1371/journal.pone.0063030.g001
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training set and employed in common feature pharmacophore
generation calculation (Figure 3). A principal value of 2 and
maximum omit feature value of 0 were assigned to the most active
compound in the training set whereas 1 was assigned for the other
compounds to label them as moderately active. For all compounds
in the training set, energy minimization process was performed
with CHARMM forcefield. Poling algorithm was applied to
generate a maximum of 255 diverse conformations with the
energy threshold of 20 kcal mol21 above the calculated energy
minimum for every compound in the dataset. These conformers
were generated using Diverse Conformer Generation protocol running
with Best/Flexible conformer generation option as available in DS.
All five training set compounds associated with their conforma-
tions were used in common feature pharmacophore generation.
HipHop module of the catalyst which was popularly known for
Common Feature Pharmacophore Generation is available in DS
as Common Feature Pharmacophore Generation protocol. Feature Mapping
protocol was used to identify the common chemical groups present
in the training set compounds. As predicted, hydrogen bond
acceptor (HBA), hydrophobic aliphatic (HY_AL) and hydrophobic
aromatic (HY_AR) features were selected during the pharmaco-
phore generation.
Validation of structure and ligand-based pharmacophore
models
The purpose of the pharmacophore validation is to evaluate the
quality of a pharmacophore model [11]. The capability to
accurately predict internal and particularly external data sets is
an important attribute of a reliable pharmacophore model [19].
The four structure-based models and best model from Hip-Hop
module were validated using three different methods: (i) test set, to
validate how well our selected pharmacophores pick the active
from inactive compounds. In order to employ test set validation
approach, a data set containing active and non-active compounds
was prepared. Structurally diverse 134 compounds with a wide
range of experimentally known chymase inhibitory activity values
(2.1 to 40 000 nM) were merged with 190 presumably inactive
compounds. This methodology of merging experimentally known
Figure 2. Crystal structure of chymase (PDBID: 3N7O). Available ligands that are co-crystallized with chymase were overlaid at the active site.
These ligands with their bound conformations were used for Receptor-ligand pharmacophore generation. Zoomed view clearly shows the
arrangement of residues at the active site.
doi:10.1371/journal.pone.0063030.g002
Figure 3. Training set compounds used in common feature
pharmacophore generation.
doi:10.1371/journal.pone.0063030.g003
Table 1. List of Solved Crystal Structures of Human Chymase
Co-Crystallized with Different Ligands.
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active compounds with presumably inactive compounds has been
successfully applied for validation of pharmacophore models in
various studies [20,21,22]. Chemical structures of test set
compounds were downloaded from BindingDB database (http://
www.bindingdb.org). Thus, a test set containing 324 compounds
was applied to determine the capability of the pharmacophore
models to discriminate active compounds from other molecules in
virtual screening process. (ii) The reliability of the generated
pharmacophore models was also validated on the basis of the
presence of chemical features essential to interact with the key
amino acids in the active site of the corresponding target protein.
(iii) Scale fit value method was also used to check the ability of
pharmacophore models to differentiate between experimentally
known chymase inhibitors based on their activity. For this
purpose, a set of chymase inhibitors with a wide range of
experimentally known chymase inhibitory activity was selected
from literature. Chemical structures of these compounds were also
downloaded from BindingDB database (http://www.bindingdb.
org).
Database preparation and multiple pharmacophore-
based virtual screening
Maybridge (http://www.maybridge.com), and Chembrige
(http://chembridge.com) which are commercial chemical data-
bases containing 59 652, and 50 000 compounds, respectively,
have been employed for virtual screening procedure. However,
these databases are found to have number of nondruglike
compounds. As, it is worthless to screen all the compounds of
these databases and then eliminate them in the later phase for their
nondruglike properties, therefore, the compounds not satisfying
druglike properties were excluded from the databases prior to
multiple pharmacophore-based virtual screening. In order to
accomplish this task, compounds in these databases were subjected
to various scrupulous druglike filters such as Lipinski’s rule of five
and ADMET (absorption, distribution, metabolism, excretion, and
toxicity) properties. Prepare Ligands and ADMET Descriptors
protocols as available in DS program were used in this step. After
preparation of druglike databases, all structure-based and ligand-
based pharmacophore models were subjected to screening of these
druglike databases. The retrieved hits were further sorted out by
applying filter such as maximum fit value of the best pharmaco-
phore models from ligand-based and structure-based models, and
were subsequently subjected to molecular docking process.
Molecular docking
Molecular docking studies were carried out using GOLD
(Genetic Optimization for Ligand Docking) 5.1 program from
Cambridge Crystallographic Data Center, UK. GOLD uses a
genetic algorithm for docking ligands into protein binding sites to
explore the full range of ligand conformational flexibility with
partial flexibility of protein [23]. Molecular docking was
performed to generate the bioactive binding poses of inhibitors
in the active site of enzyme. Protein coordinates from the crystal
structure of chymase co-crystallized with N7O (PDB ID: 3N7O),
determined at a resolution of 1.8Å were used to define the active
site. All the water molecules present in the protein structure were
removed and hydrogen atoms were added. The active site was
defined with a 10 Å radius around the ligand present in the crystal
structure. Ten docking runs were performed per structure unless
three of the 10 poses were within 1.5 Å RMSD of each other. All
the hit compounds as well as training set compounds were docked
into chymase binding site. The GOLD fitness score is calculated
from the contributions of hydrogen bond and van der Waals
interactions between the protein and ligand, intramolecular
hydrogen bonds and strains of the ligand. The interacting ability
of a compound depends on the fitness score, greater the GOLD
fitness score better the binding affinity. The protein – ligand
interactions were examined by DS. Hit molecules which showed
the expected interactions with the critical amino acids present in
the active site of the protein, and comparable high binding scores
than the bound ligand, were selected as potent inhibitors of
chymase.
Molecular docking validation using autodock 4.2
Autodock 4.2 was used to calculate the binding energies of the
hit compounds at the active site of chymase [24]. The starting
protein was prepared from the 1.8 Å resolution crystal structure of
chymase labeled as 3N7O. We have chosen the highest resolution
chymase crystal structure from the Protein Data Bank. Final hits
along with training set compounds were docked using the
Lamarckian genetic algorithm (LGA) in the ‘‘docking active site’’,
defined through a grid centered on the ligand of the complex
structure. Population size of 150, mutation rate of 0.02, and
crossover rate of 0.8 were set as the parameters. The default grid
spacing (0.375 Å) was used. Simulations were performed using up
to 2.5 million energy evaluations with a maximum of 27 000
generations. Each simulation was performed 10 times, yielding 10
docked conformations. The lowest energy conformations were
regarded as the binding conformations between ligands and the
protein.
Validation of synthetic accessibility for hit compounds
using SYLVIA
Synthetic accessibility scores for all four hit compounds were
used to validate the synthetic possibilities. SYLVIA v 1.0 program
from the Molecular Networks group was employed to calculate the
synthetic accessibility of these optimized compounds [25]. The
estimation of synthetic accessibility using SYLVIA provides a
number between 1 and 10 for compounds that are very easy to
synthesize and compounds that are very difficult to synthesize,
respectively. The method for calculating synthetic accessibility
takes account of a variety of criteria such as complexity of the
molecular structure, complexity of the ring system, number of
stereo centers, similarity to commercially available compounds,
and potential for using powerful synthetic reactions. These criteria
have been individually weighted to provide a single value for
synthetic accessibility.
Density Functional Theory (DFT) calculations
In the present study, we carried out a DFT-based quantitative
structure–activity relationship (QSAR) study for both experimen-
tally known chymase inhibitors and final hits. To obtain a
significant correlation, it is fundamental that apposite descriptors
be employed, whether they are theoretical, empirical, or
experimental features of the structures. DFT is today one of the
best methods to study medium size and larger molecular systems
[26,27]. The best DFT methods achieve substantially greater
precision than the Hartree–Fock theory at only a modest augment
in cost. They accomplish this task by incorporating few effects of
electron correlation much less affluently than traditional correlated
methods. A range of functional has been defined, generally
distinguished by the manner that they treat the exchange and
correlation components. The best known of the hybrid functionals
is Becke’s three-parameter formulation B3LYP [28]. Complete
geometry optimization for data set compounds was carried out
using DFT with B3LYP, using basis set 6-31G* level. A useful kind
of net atomic charges, called electrostatic potential (ESP)-fitting
Chymase Hits with Novel Chemical Scaffolds
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charges, were derived from the DFT calculated molecular
electrostatic potential distribution using CHelpG method, which
produces charges fit to the electrostatic potential at points selected.
Vibrational frequencies were computed at the same B3LYP/6-
31G* level to characterize the stationary points on the corre-
sponding potential energy surfaces. All calculations were per-
formed using the Gaussian 09 suite of programs.
The experimentally known and highly active chymase inhibitors
with substantial structural diversity which were used for the
common feature pharmacophore generation were selected for
DFT calculations. Moreover, four final hits KM09155,
HTS00581, HTS0589, and Compound1192 retrieved from
databases by the selected pharmacophore models, which showed
important results with respect to all properties like key molecular
interactions with the active site components, calculated drug-like
Figure 4. Representation of structure-based pharmacophore models with their geometric constraints. Cyan color shows hydrophobic
(HY); magenta indicates hydrogen bond donor (HBD); green color indicates hydrogen bond acceptor (HBA); brown color denotes to ring aromatic
(RA); and negative ionizable (NI) is shown in blue color.
doi:10.1371/journal.pone.0063030.g004
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properties, and high GOLD fitness score, were also designated for
DFT study. Various quantum-chemical descriptors such as
LUMO, HOMO, and locations of molecular electrostatic
potentials (MESP) were computed.
Calculation of molecular electrostatic potential (MESP)
For investigation of biologically active compounds, the mapping
of the electrostatic potential is a well-known approach because it
plays a key role in the initial steps of ligand-receptor interactions
[29,30,31]. The formatted checkpoint files of the compounds
generated by the geometric optimization computation were
employed as input for CUBEGEN program interfaced with
Gaussian 09 program to compute the MESP. The MESP
isopotential surface was produced and superimposed onto the
total electron density surface (0.0004 e/au3). The electrostatic
potential of the whole molecule was finally obtained by
superimposing the electrostatic potentials upon the total electron
density surface of the compound.
Results and Discussion
Generation of structure-based pharmacophore models
The Receptor-Ligand Pharmacophore Generation protocol of DS
presents the chemical features which instigate key interactions
between protein and ligand as well as some excluded volume
spheres corresponding to the 3D structure of protein. In this study,
four different 3D structures of chymase bound with its inhibitors
such as 3N7O, 1T31, 3SON, and 2HVX were selected as input
for structure-based pharmacophore generation [9,32,33,34]. The
generated four pharmacophore models along with their excluded
volume spheres and geometrical constrain are illustrated in
Figure 4. The excluded volume spheres presented in our models
provide an insight regarding the disallowed regions in the binding
site. In general, these excluded volumes attempt to penalize
molecules occupying steric regions that are not occupied by active
molecules. Refinement of the pharmacophore with these excluded
volume features provides a more selective model to reduce false
positives and a better enrichment rate in virtual screening. In an
attempt to account protein flexibility and reorganization effects at
the pharmacophore level, the size of the excluded volume was set
to 5Å to increase the effective size of the binding cavity. For 3N7O
complex, the generated structure-based pharmacophore model
(SB_ Model1) identified five functional features along with 20
excluded volume spheres, including one HBD pointed towards
Ser214, one NI pointed to Lys40, and three HY centers pointed
towards Tyr215, Gly216, and Leu99 amino acids, respectively.
Pharmacophore model (SB_Model2) with four distinct features
was generated from 1T31 complex. It composed of one HBA, one
NI, one HY, and one RA with 20 excluded volume spheres. The
HBA and NI features were directed to Gly193 and Lys192,
respectively. While, RA feature of the SB_Model2 was pointed
towards His57 amino acid of the active site of chymase. The
pharmacophore model (SB_Model3) developed from 3SON
complex also consists of four features with two HY features
pointing in the direction of Gly199 and Arg200, one NI, and one
RA pointing towards His45 along with 16 excluded volume
spheres. The final pharmacophore model (SB_Model4) derived
from 2HVX complex showed six features encompassing one
HBD, two HY, two NI, and one RA with 23 excluded volume
spheres. The two HY groups were pointed towards Phe191 and
Gly216, and HBD pointed towards Tyr215. While, the RA feature
was directed towards His57 and two NI features were pointed in
the direction of Lys192 and Gly193. The comparison of above
four pharmacophore models showed that hydrophobic feature was
the common feature among all developed pharmacophore models.
Figure 5. Ligand-based pharmacophore model (LB_Model) and
its overlay on most active compound of training set.
doi:10.1371/journal.pone.0063030.g005
Table 2. Summary of the Pharmacophore Models Generated








Hypo1 ZZHAAA 79.084 11111 00000 6
Hypo2 RZHAAA 78.571 11111 00000 6
Hypo3 RZHAAA 78.285 11111 00000 6
Hypo4 RRHAAA 77.768 11111 00000 6
Hypo5 RZHAAA 76.653 11111 00000 6
Hypo6 ZZHAAA 74.628 11111 00000 6
Hypo7 RZHAAA 74.583 11111 00000 6
Hypo8 RZHAAA 74.053 11111 00000 6
Hypo9 RRHAA 72.502 11111 00000 5
Hypo10 RRHAA 72.502 11111 00000 5
doi:10.1371/journal.pone.0063030.t002
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A previous study also showed that presence of hydrophobic sites
for a chymase inhibitor were important for its effective binding
with the key residues of the active site [35]. Pharmacophoric
features of the models were directed towards key amino acids like
Tyr215, His57, Lys192, Gly193, and Ser195 which play a major
role in chymase inhibition activity [9,34]. Hence, these features
can be considered as important chemical features to discover the
novel chymase inhibitors.
Generation of ligand-based pharmacophore model
Common feature pharmacophore models were generated for
the target protein using set of experimentally known inhibitors.
With the aim of acquiring a best model, numerous common
feature pharmacophore generation runs were performed by
altering the parameters such as minimum interfeature distance
values, maximum omit feature, and the permutation of pharma-
cophoric features. The qualitative top ten pharmacophore models
were developed (Table 2) using Common Feature Pharmacophore
Generation/DS to identify the common features necessary to inhibit
chymase. Direct and partial hit mask value of ‘1’ and ‘0’ for
models connoted that the molecules present in dataset were well
mapped to all the chemical features in the models and there is no
partial mapping or missing features. The Cluster analysis was used to
evaluate and categorize the difference between the compositions of
models’ chemical features and locations. These models could be
roughly classified into two clusters according to the pharmaco-
phoric features presented. The first eight models in cluster I
identified six functional features, including three HBA, hydropho-
bic aromatic (HY_AR), hydrophobic aliphatic (HY_AL), and ring
aromatic (RA) centers. The models in cluster II recognized five
functional features, with two HBA, one HY_AL, and two RA. The
distances between some pharmacophoric features in all models
were rather constant, whereas some distances fluctuated in a
relatively broad range, which indicated divergent tolerance of
different features to spatial variation and provided rationale for
further structural modification and optimization. As three models
in cluster I showed higher ranking score and best fit values of the
training set compounds, therefore these models were further
evaluated to find the best model. There is not much difference in
the ranking score among these models; therefore, an analysis of the
best fit values of the training set compounds was carried out to
choose the best model. The calculated best fit values designated
Model 1 as the best and final ligand-based model (LB_Model)
(Figure 5A). This final LB_Model which consists of three HBA,
one HY_AL and two HY_AR features was further overlaid on the
most active compound of training set (Figure 5B). The prevalence
Figure 6. ROC curves generated for structure-based pharmacophore models by DS.
doi:10.1371/journal.pone.0063030.g006
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of HBA features in LB_Model derived from experimentally known
inhibitors indicated that these chemical features were essential for
the inhibition of chymase. A previous study also illustrated that
HBA features in chymase inhibitors improve its binding affinity to
the active site of chymase [36].
Validation of structure and ligand-based pharmacophore
models
A valid pharmacophore model should be not only statistically
robust, but also predictive to internal and external data sets. Its
capability to reliably predict external data sets and discriminate
active inhibitors from other molecules is critical criteria for high-
quality models. In this study, two validation methods are used to
validate the quality of generated pharmacophore models which
are as following.
Test set method
In order to perform test set validation technique which is
considered as a meaningful approach to validate the discriminative
power of a pharmacophore model in virtual screening, 134
compounds with a wide range of experimentally known chymase
inhibitory activity values (2.1 to 40 000 nM) were used with 190
presumably inactive compounds. Thus, a test set containing 324
compounds was prepared for validation of pharmacophore
models. All four structure-based pharmacophore models were
validated using validation option of the Receptor-Ligand Pharmaco-
phore Generation protocol of DS. By using this option of validation,
both sensitivity and specificity of the models were calculated.
Moreover, ROC curve was also generated for each structure-
based pharmacophore model (Figure 6). SB_model1 with accuracy
rate of 0.802, showed best predicted ability with high sensitivity
and specificity. While, SB_mode3 with accuracy rate of 0.621
exhibited lowest predicted ability. The statistically significant
parameters related to this validation technique are listed in Table 3
which clearly indicate that SB_Model1, SB_Model2, and
SB_Model4 were able to distinguish between active and non-
active compounds more precisely than SB_Model3. Therefore,
these three models were selected for further evaluation. The
ligand-based model (LB_Model) was also validated with the test set
method. Ligand Pharmacophore Mapping protocol running with
BEST/Flexible conformation generation option was used to map
the test set compounds. LB_Model was able to predict 118 from
total of 134 active compounds. Thus, it exhibited good sensitivity
and specificity and was designated for further processing.
Presence of chemical features essential to interact with
key active site residues
Another method employed to validate the quality of all four
phrmacophore models was the evaluation of models for the
presence of chemical features required to interact with key active
site residues. To find out the existence of chemical features that are
complementary to the active site, diagrams were generated for the
chymase-inhibitor complexes by using DS which illustrated the
amino acids complemented to every feature present in the
pharmacophore models (Figure 7). Overlay of the bound inhibitor
on SB_Model1 connoted that chemical features of pharmaco-
phore model were located in such a way to interact with important
amino acids like Tyr215, Lys40, and Gly193. Chemical features of
SB_Model2 were also oriented towards key amino acids like
His57, Gly193 and Lys192. SB_Model4 also exhibited chemical
features pointed to key residues of active site such as Lys192,
Gly193, and Tyr215. In case of ligand-based pharmacophore
model, the overlay of most active compound of the training set on
LB_Model and docking of this compound into the active site of
chymase clearly demonstrated that the three HBA, two HY_AR,
and one HY_AL features of LB_Model have engendered
numerous imperative interactions with key amino acids such as
Lys40, His57, Lys192, Gly193, and Ser195 (Figure 8A). Thus,
presence of chemical features essential to interact with key active
site residues and discriminative power of developed models to
active chymase inhibitors implicated that multiple pharmaco-
phore-based virtual screening may provide an efficient approach
to find novel chymase inhibitors from available databases.
Scale fit value method
Third method to validate the generated ligand and structure-
based pharmacophore models is the scale fit value method. The
main purpose of this validation method is to verify the ability of
pharmacophore models to distinguish between experimentally
known chymase inhibitors based on their activity values. A set of
20 chymase inhibitors with diverse range of activity values from
1 nM to 1800 nM was selected and mapped over generated
pharmacophore models. Results of this pharmacophore mapping
over chymase inhibitors returned various fit values. A meticulous
analysis of these fit values revealed that there was a good
correlation between experimentally known activity values and fit
values generated by pharmacophore mapping (Figure 8B). Thus,
the result of this validation technique clearly indicates that the
selected ligand and structure-based pharmacophore models have
the capability to single out most active inhibitors form less active
chymase inhibitors.
Table 3. Statistical Details of Test Set Validation Method Using DS.














SB_Model1 134 190 129 47 143 5 0.96269 0.24737
SB_Model2 134 190 127 67 123 7 0.94776 0.33158
SB_Model3 134 190 62 141 49 72 0.46269 0.74211
SB_Model4 134 190 111 103 87 23 0.82836 0.54737
LB_Model 134 190 118 79 111 16 0.88060 0.41579
doi:10.1371/journal.pone.0063030.t003
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Multiple pharmacophore-based virtual screening
To further validate representative pharmacophore models and
demonstrate their efficiency, SB_Model1, SB_Model2, SB_
Model4, and LB_Model were used as 3D queries to screen the
chemical databases like Maybridge and Chembridge which consist
of 59 652 and 50 000 compounds, respectively. Prior to multiple
pharmacophore-based virtual screening experiments, both data-
bases were transformed to druglike databases by Prepare Ligands and
ADMET Descriptors protocols of DS. After preparation of druglike
databases, all four pharmacophore models were subjected to
screening of these druglike databases. For SB_Model4 which holds
six features, Maximum omitted feature was set to 1 and for all
other three models it was set to 0. The retrieved database hits were
then ranked by their fit scores and the sorted list of hit compounds
was analyzed to generate the final hits for each pharmacophore
model. The hits acquired by the structure-based pharmacophore
models with fit values above 2.0 were considered as potential hits
and were reserved for further inspection. For LB_Model, fit value
was set to3.5. The numbers of final hit compounds predicted by
each of the four pharmacophore models from both databases are
summarized in Table 4. It is observed that even for the same
target, the hits retrieved by diverse pharmacophore models are
quite distinguished from each other hence signifying that different
pharmacophore models may show assorted output in virtual
screening experiments. However, there were few common hits
which were retrieved by more than one pharmacophore models.
In order to decipher the proportion of common hits between
various models, the overlap segment of the hit compounds
obtained by each pair of two diverse pharmacophore models
was evaluated. Analysis revealed that ratio of common hits among
all four pharmacophore was between 18 and 32% thus showing
the diversity in screening competency of different pharmacophore
models derived from different complex structures of same enzyme.
Consequently, multiple pharmacophore model-based screening
approach should be applied to acquire better screening results.
Finally, 133 hits compounds retrieved from database screening
process were subjected to molecular docking studies.
Molecular docking
Docking experiments can be employed to answer various
queries. For instance, position and orientation of an inhibitor or
substrate can be predicted. An attempt to identify compounds that
have affinity for the protein from a large database of compounds
can be made. Moreover, prediction for any given molecule
whether or not it has affinity for the protein, can also be done.
Herein, we will present and discuss our docking experiments to
address these issues for the chymase enzyme.
Validation of ligand binding mode
Docking study has been performed with GOLD 5.1. An initial
validation of the docking protocol is performed by comparing the
conformation, position, and orientation (the pose) of a ligand as
obtained from docking with the one determined experimentally
with X-ray crystallography. Correctly redocking the crystallo-
graphically observed inhibitor is a minimum requirement to
determine whether the program is applicable to this system or not.
Crystal structure with the PDB code 3N7O bound with an
inhibitor molecule (N7O) was selected as receptor and the active
site was defined with a 10 Å radius around the ligand present in
the crystal structure. The top conformation of ligand predicted by
GOLD program was very close to the crystal structure-bound
conformation. The RMSD between the docked pose and its bound
conformation in the crystal structure is 0.53 Å indicating that
GOLD is able to reproduce correct pose (Figure 9).
Identification of hit compounds
After validation of the docking protocol, all 133 hits retrieved by
employing a multiple pharmacophore model-based screening,
were docked into the active site of chymase. Analysis of docking
results indicated that bound ligand in the complex structure of
chymase showed GOLD fitness score of 62.58. While, among 133
hit compounds, 21 hits demonstrated higher GOLD fitness score
Figure 7. Overview of the interaction mode between chymase
and known inhibitors at the active site of enzyme. (A)
SB_Model1 mapped to N7O, (B) SB_Model2 mapped to OHH, (C)
SB_Model4 mapped to DRX. Key amino acids involved in the interaction
were displayed (gray: C atoms; red: O atoms; blue: N atoms).
doi:10.1371/journal.pone.0063030.g007
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than the ligand bound with crystal structure, thus, were selected
for further study. In order to obtain hits which could map all
available bioactive conformations at the active site of chymase,
these 21 hit compounds were further docked to the other two
crystal structures of chymase labeled as 1T31 and 2HVX. These
two crystal structures were also employed for the development of
SB_Model2 and SB_Model4. Analysis of their docked results
helped in further filtering of hit compounds. Finally, four hit
compounds which showed the key interactions with the critical
amino acids present in the active site of protein and also exhibited
higher fitness score in all three crystal structures of chymase were
selected as final hits. The final hits which included KM09155,
HTS00581, and HTS05891 compounds, were retrieved from
Maybridge database. While, fourth hit Compound1192 was
retrieved from Chembridge database. Remarkably, all final hits
were identified by four different pharmacophore models.
KM09155 was revealed by LB_Model with fitness value of 4.36.
Although, there were three compounds retrieved by LB_Model
which showed high fitness scores than KM09155, however, could
not show high fitness score for structure-based models. Therefore,
these compounds were not selected as final hits. The HTS00581
hit was spotted by SB_Mode2 with fitness value of 3.83. While, the
third hit compound HTS05891 was also marked by SB_Mode2
with 3.68 fitness score. The fourth final hit Compound1192 was
identified by two different pharmacophore models including
SB_Mode1 and SB_Mode4 with fitness scores of 3.50 and 3.72,
respectively. Structural diversity of final hits was measured by
using Calculate Diversity Metrics protocol of DS which calculates a
series of quantitative measures of diversity including number
fingerprint features, number assemblies, fingerprint distances,
property distances and fraction cells. Result with Diversity_NumAs-
semblies value of 1.0 designated the final hits very high structural
diversity. Therefore, it is quite evident that multiple pharmaco-
phore-based virtual screening experiments merged with molecular
docking studies are very competent tools for the identification of
diverse hits in the drug discovery process.
Validation of final hits using Autodock and SYLVIA
The binding modes of the potential chymase hits were further
evaluated by using AutoDock 4.2 docking programs. The starting
protein was prepared from the 1.8 Å resolution crystal structure of
the 3N7O complex. Final four hits along with training set
compounds were docked using the Lamarckian genetic algorithm
(LGA) in the ‘‘docking active site’’, defined through a grid
(coordinates: X = 212.224, Y = 245.425, Z = 255.878). Al-
though, AutoDock consumes more calculation time yet envisages
the binding conformations more precisely [37]. It also computes
Figure 8. Ligand-protein interaction diagram from the chymase-inhibitor (compound 1 in the training set of chymase). (A). The
pharmacophore mapping of the same compound is also depicted. HBA, hydrogen bond acceptor; HY_AR, hydrophobic aromatic, HY_Al,
hydrophobic aliphatic. The locations of amino acid residues are represented in rectangular boxes, where pink and green colors denote both the
hydrogen bond acceptor/donor and nonpolar contacts, respectively (B) Correlation graph between experimental IC50 and scale fit values.
doi:10.1371/journal.pone.0063030.g008
Table 4. The Database Screening Results by Different
Structure-based and Ligand-based Pharmacophore Models.






Figure 9. Overlay of the docked pose (green) of inhibitor with
its crystal structure conformation (yellow).
doi:10.1371/journal.pone.0063030.g009
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torsional energy which gives rise to the binding energy of the
docked compound. Autodock result signified that all the four hit
compounds had scored similar or better binding energy values
compared to the most active compound in the training set thus
validating the output of GOLD docking program. In order to
further validate final hit compounds, two more crystal structures of
chymase deposited in protein data bank labeled as 1T31 and
2HVX were used for AutoDock validation. The resultant binding
energies of hits with these structures also showed better or equal
values compared to the binding energies of experimentally known
potent chymase inhibitors present in the training set. To further
validate our inhibition strategy, the synthetic accessibility of the
final four hits was also measured using SYLVIA 1.0 program. The
synthetic accessibility of most active compound 1 of the training
set was also calculated for comparison purpose. The SYLVIA
score of 6.19 for compound 1 was much high than the scores of
final hits. Thus, the SYLVIA score for the final hits clearly
illustrates that these compounds are easy to be synthesized
(Table 5).
Binding mode analysis of hits
The 2D chemical structures of four hit compounds KM09155,
HTS00581, HTS05891, and Compound1192 which were selected
from the multiple pharmacophore-based screening and molecular
docking studies, are illustrated in Figure 10. For all three crystal
structures of chymase, the GOLD fitness score and the calculated
Table 5. GOLD Fitness Scores, AutoDock Binding Energies, and SYLVIA Synthetic Accessibility Scores of Potential Chymase


















KM09155 77.533 25.99 70.383 25.68 73.365 26.8 2.96
HTS00581 66.979 24.66 66.915 26.68 75.212 27.73 4.68
HTS05891 64.781 26.95 69.162 27.06 67.096 27.84 4.16
Comp.1192 63.872 26.86 65.870 27.55 64.419 27.09 4.15
doi:10.1371/journal.pone.0063030.t005
Figure 10. Identified hit compounds for chymase inhibition are overlaid on LB_Model, SB_Model1, SB_Model2, and SB_Model4,
respectively.
doi:10.1371/journal.pone.0063030.g010
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binding energy values of final hits are given in Table 5. Moreover,
the orientation and important interactions of the final hits with the
key residues within the active site of chymase are shown in
Figure 11. The analysis for binding mode of final hits within the
active site region of enzyme is presented below.
Binding mode of KM09155
This hit compound revealed very high GOLD fitness scores for
all three crystal structures of chymase as compared to other three
hits. KM09155 with maximum GOLD fitness score of 77.533 and
minimum binding energy of 26.88 kcal/mol established a
network of interactions with key amino acids like Ser195,
Lys192, Ser214, and Gly216. The sulfur atom of the N-phenyl-
2-sulfanylacetamide chemical moiety in KM09155 formed non-
bonded electrostatic interaction with the carbonyl oxygen atom of
Ser195. Carbonyl oxygen of N-phenyl-2-sulfanylacetamide also
interacted with the nitrogen atom of Lys192. Moreover, imper-
ative p…s interactions between the phenyl ring system of
KM09155 and the central carbon of Gly216 were also revealed.
Important hydrogen bonded interactions were also elucidated
between 4-methyl-4H-1,2,4-triazole ring of KM09155 and Ser195
and Gly216 amino acids. Although, KM09155 was revealed by
LB_Model from database, it also mapped key features of other
three structure-based pharmacophore models. Pharmacophoric
overlay of this compound upon all four models is depicted in
Figure 10.
Binding mode of HTS00581
This compound was predicted with top GOLD fitness score of
75.212 and binding energy of 27.73 kcal/mol. At the active site of
chymase, this compound has established various important close
contacts with key amino acids. For instance, carbonyl oxygen atom
of acetic acid group in HTS00581 hit compound fashioned
hydrogen bond interaction with oxyanion hole formed by Ser195
and Gly193 amino acids. The p…s interactions between the side
chain imidazole ring of His57 and piperidine moiety of hit
compound were also observed. This compound has gained
substantial hydrophobic interactions at the active site region of
enzyme. The SB_Model2 with four distinct chemical features
including one HBA, one NI, one HY, and one RA retrieved
HTS00581 hit compound from database with fitness score of 3.83.
The mapping of HTS00581 hit over SB_Model2 is illustrated in
Figure 10. Furthermore, along with the mapping of SB_Model1
and SB_Model4, the HTS00581 compound was also mapped over
LB-Model in order to find out, whether this hit compound
possesses the very basic chemical features which are present in
currently available chymase inhibitors. It mapped all the features
of LB-Model thus indicating the complimentary features that
facilitate strong enzyme-ligand binding interactions.
Binding mode of HTS05891
The binding mode of this hit compound at the active site of
chymase has illustrated various kinds of interactions such as
hydrogen bonding, p…cationic, and hydrophobic interactions with
key residues in the active site region. An important p…cationic
Figure 11. The molecular docking results. The binding modes and molecular interactions of hit compounds at the binding site of chymase
enzyme: (A) KM09155, (B) HTS00581, (C) HTS05891 from Maybridge database, and (D) Compound1192 from Chembridge database. The key active
site residues and inhibitors are shown in stick and ball-stick forms, respectively.
doi:10.1371/journal.pone.0063030.g011
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interaction between the 5-methylisoxazole ring of hit compound
and nitrogen atom of Lys192 was elucidated. The presence of this
electrostatic interaction lead to the binding orientation of hit
compound in more favorable way which instigated key interac-
tions with other key residues like Gly193 and Ser195. The oxygen
atom of carbonyl group in hit compound formed very close
hydrogen bond interaction to hydrogen atom of Gly193. Another
key hydrogen bonding interaction was also observed between
HTS05891 hit and Ser195 amino acid. Considerable hydrophobic
interactions were also observed between the hit compound and
active site of chymase. The HTS05891 hit was spotted by
SB_Model2 from database and the overlay of pharmacophoric
features of SB_Model2 on the compound is depicted in Figure 10.
Moreover, this hit compound mapped all the features of LB-
Model which contains essential chemical features present in
experimentally known potent chymase inhibitors. It also mapped
five features of the Sb_Model3. HTS05891 exhibited high GOLD
fitness scores for all three crystal structures of chymase used in this
docking study. The maximum GOLD fitness score of this
compound for chymase binding is 67.096 with the binding energy
of 27.84 kcal/mol.
Binding mode of compound 1192
With maximum Gold fitness score of 65.870 and binding energy
of 27.55 kcal/mol, this hit compound has established numerous
close contacts that lead to the important ligand-enzyme interaction
such as hydrogen bonding interactions with Gly193, Ser195,
Phe191 and hydrophobic interactions with Gly216 and Arg217
amino acids in the active site of the enzyme (Figure 11). The
oxygen atom of formic acid group present in compound1192 has
shown close hydrogen bonding interaction with the nitrogen atom
of Gly193. Hydrogen bonding was also observed between
carbonyl group and Ser195 amino acid which is an important
residue in the active site of chymase enzyme. Additional hydrogen
bonding interactions were also elucidated between Phe191 and
Arg217. Compound1192 was marked from database by two
pharmacophore models including SB_Model1 and SB_Model4.
This hit compound also mapped all the pharmacophoric features
of SB_Model2. However, it missed one of the HBA features of
LB_Model and mapped five features out of six for this
pharmacophore model. As, compound1192 has mapped well four
structure-based and ligand-based pharmacophore models, there-
fore, it indicates the presence of features imperative for strong
enzyme-ligand binding interactions. The overlay of all four models
on hit compound1192 is depicted in Figure 10.
Density Functional Theory (DFT) Calculations
Electronic attributes. According to Frontier Orbital Theo-
ry, the shapes and symmetries of the HOMO and LUMO are
crucial in predicting the reactivity of a species and the
stereochemical and regiochemical outcome of a chemical reaction.
Consequently, the outcome of these quantum chemical descrip-
tors, direct us to distinguish the reactive sites and substituent
influence on electronic structure of the compounds. Maps of
HOMO and LUMO are plotted onto the molecular surfaces of all
four hit compounds along with most active compound 1 of the
training set (Figure 12). Inspection of variations in these maps of
molecular orbitals indicates that electron exchange and electron-
transfer ability of the compounds may have a role in their anti-
chymase activity. The HOMO map delineates the area that is
most electron-sufficient. Analysis of HOMO maps of compounds
illustrate that HOMO molecular orbitals are located on aromatic
and the heteroaromatic rings which contain the heteroatoms such
as nitrogen and oxygen. While, inspection of LUMO plots
demarcated the regions that can act as electron acceptors to the
active site of the chymase. Amide groups and heteroaromatic rings
were the most often groups in hit compounds occupied by LUMO
orbitals. These results are quite consistent with the docking
analysis which illustrates the participation of these moieties in the
key ligand-receptor interactions. A previous experimental study
also inferred that introduction of heteroatoms to the inhibitor
compound enhanced its stability in human plasma [18]. For
instance, the placement of an ethoxy group in compound 2
instigated its stability. Thus, the analysis of two frontier orbitals
clearly indicates an important role of charge-transfer interactions
with the binding site in the receptor for potent activity. Electron
donating or withdrawing groups in the compounds may be
responsible for an increase or decrease in the orbital energies by
allowing modulation of the molecular electronic ‘‘band gaps’’.
Molecular electrostatic potential (MESP) profiles
Electrostatic potential characteristics are considered to be key
features of molecules through which it recognizes its receptor. The
molecular electrostatic potential surface MESP which is a plot of
electrostatic potential mapped onto the iso-electron density
surface, simultaneously displays molecular shape, size and
Figure 12. Plots of HOMO and LUMO of most active compound
1 along with potent hits KM09155, HTS00581, HTS05891 and
Compound1192.
doi:10.1371/journal.pone.0063030.g012
Chymase Hits with Novel Chemical Scaffolds
PLOS ONE | www.plosone.org 13 April 2013 | Volume 8 | Issue 4 | e63030
electrostatic potential values. MESP mapping is very useful in the
investigation of the molecular structure with its physiochemical
property relationships. Nam et al. reported their discovery that
electrostatic interactions accounted for the majority of the rate
acceleration in the mechanism of RNA transphosphorylation in
solution catalyzed by the hairpin ribozyme [38]. Moreover, the
electrostatic funnel illuminated from three-dimensional mapping
of the electrostatic potential was reported by Dehez et al., driving
the diphosphate nucleotide rapidly toward the bottom of the
internal cavity of membrane-protein mitochondrial ADP/ATP
carrier by forming a privileged passageway [39]. Taking into
account these findings comprehensively, we assumed that the
electrostatic potential of the inhibitor also played a important role
in the binding and interaction with chymase together with orbital
energy and consequently influenced the inhibition effect. The 3D
MESP plots of hit compounds were superimposed inside the active
site of chymase (Figure 13). The coloring area of the surface
represents the overall molecular charge distribution with the
electrostatic potential. As for the compounds in this study, the
electronegative potential (MESPmin) was coded with red on the
MESP maps while the interpolated blue map represents the
electropositive potential (MESPmax) of a strongest repulsion. The
predominance of green region in the MESP surfaces corresponds
to a potential halfway between the two extremes that are indicated
in red and blue colors, respectively. The MESP plotted onto
constant electron density surface for KM09155 hit showed the
most electropositive potential region at the methyl of 4-methyl-4H-
1,2,4-triazole ring and the most electronegative potential region
was spread over the oxygen atoms of the both carbonyl groups
present in KM09155. In other hit compounds, hydrogen atoms
attached with heteroatom like oxygen and nitrogen are the regions
which bear the maximum brunt of positive charge. Moreover, a
gradual depletion of both red and blue areas and an increase of
green color around the aromatic rings were also observed. On the
whole, appearance of both most electronegative and electropos-
itive regions along with moderate section in hit compounds
demonstrates that these regions can act as electron donors or
acceptors to the active site of the chymase thus making these
compounds very reactive. Docking results of these compounds also
signified the participation of these areas in the imperative
interactions with the key active site residues such as Ser195,
Gly193, His57, Tyr215 and Phe191 of the enzyme.
Conclusions
A deriving pharmacophore model from the three-dimensional
structure of a target protein provides helpful information for
analyzing protein-ligand interactions and further improvement of
ligand binding affinity. While, pharmacophore model derived
from already known inhibitors facilitates in the identification of
essential chemical features present in experimentally known potent
chymase inhibitors. To find novel and potent chymase inhibitors
and to provide a new idea for drug design, we used both ligand-
based and structure-based methods to perform the virtual
screening (VS) of commercially available databases. As different
Figure 13. Differential maps of MESP for final hit compounds KM09155, HTS00581, HTS05891 and Compound1192. The red and the
blue color represent the electronegative and electropositive potentials whereas the green represents a potential halfway between the two extremes.
doi:10.1371/journal.pone.0063030.g013
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pharmacophore models generated from different crystal structures
may represent different inhibitor binding modes. Therefore,
multiple pharmacophore-based virtual screening approach can
be more efficient way in identification of potent hits that can bind
to various bioactive conformations available in the active site of
enzyme. X-ray crystallographic data of chymase in complex with
different inhibitors were used to generate four structure–based
pharmacophore models. A common feature pharmacophore
model was also developed from experimentally known inhibitors.
After successful validation of developed pharmacophore models, a
smart virtual screening strategy was conducted by employing all
pharmacophore models to retrieve hits with novel chemical
scaffolds. Drug-like hit compounds were subjected to molecular
docking using GOLD and AutoDock to evaluate compounds for
important binding site interactions and affinity. Finally four
structurally diverse compounds with high GOLD score and
binding affinity for several crystal structures of chymase were
selected as final hits. Identification of final hits by four different
pharmacophore models necessitates the use of multiple pharma-
cophore-based approach in VS process. Quantum mechanical
(QM) calculation is also conducted for analysis of electrostatic
characteristics of compounds. Inspection of the molecular
electrostatic potential surfaces and frontier molecular orbitals
successfully explained their significant role in driving the inhibitor
to adopt a suitable bioactive conformation oriented in the active
site of enzyme. In general, this study is used as example to illustrate
how multiple pharmacophore approach can be useful in
identifying structurally diverse hits which may bind to all possible
bioactive conformations available in the active site of enzyme. The
present study may lead to the knowledge of chemical properties
which are likely to improve activity of already known chymase
inhibitors and may also allow the modification of the structure of
new chemical entities (drug) for the improved bioavailability. The
application of multiple pharmacophore-based VS can also be
extended to the development of fast-follower drugs, where more
than one high-quality crystal structures of the target in complex
with potent ligands are already available. Therefore, the multiple
pharmacophore modeling approach can be very useful in virtual
screening of any chemical database for the development of new
potent inhibitors for the enzyme.
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